Haemonetics Croissance future
Future contrôle des critères 4/6
Haemonetics devrait augmenter ses bénéfices et son chiffre d'affaires de 26.4% et de 7% par an respectivement. Le BPA devrait croître de de 26.3% par an. Le rendement des capitaux propres devrait être 25.9% dans 3 ans.
Informations clés
26.4%
Taux de croissance des bénéfices
26.3%
Taux de croissance du BPA
| Medical Equipment croissance des bénéfices | 17.5% |
| Taux de croissance des recettes | 7.0% |
| Rendement futur des capitaux propres | 25.9% |
| Couverture par les analystes | Good |
| Dernière mise à jour | 24 Oct 2024 |
Mises à jour récentes de la croissance future
Recent updates
These 4 Measures Indicate That Haemonetics (NYSE:HAE) Is Using Debt Reasonably Well
Sep 09
What You Can Learn From Haemonetics Corporation's (NYSE:HAE) P/E
Aug 14Are Investors Undervaluing Haemonetics Corporation (NYSE:HAE) By 46%?
Jul 18Haemonetics Undervalued As It Passes Into A Period Of Softer Reported Growth
Jun 21Does Haemonetics (NYSE:HAE) Deserve A Spot On Your Watchlist?
Apr 30Haemonetics Corporation's (NYSE:HAE) Share Price Matching Investor Opinion
Apr 12Haemonetics Corporation (NYSE:HAE) Shares Could Be 35% Below Their Intrinsic Value Estimate
Mar 07Haemonetics Corporation: Improved Performance, Another Bolt-On Deal
Mar 06The Strong Earnings Posted By Haemonetics (NYSE:HAE) Are A Good Indication Of The Strength Of The Business
Feb 15The Price Is Right For Haemonetics Corporation (NYSE:HAE)
Jan 01Haemonetics: Solid Performance Of This Blood Play
Nov 22Here's Why We Think Haemonetics (NYSE:HAE) Might Deserve Your Attention Today
Nov 14Is Haemonetics (NYSE:HAE) A Risky Investment?
Oct 24Haemonetics Offers Relatively Rare Momentum In A Tough Medical Device Environment
Oct 13Haemonetics' Fiscal Q1 2024: Blood, Sweat, And Stellar Gains
Aug 09Here's Why Haemonetics (NYSE:HAE) Has Caught The Eye Of Investors
Aug 09An Intrinsic Calculation For Haemonetics Corporation (NYSE:HAE) Suggests It's 48% Undervalued
Jul 25Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet
Jul 07Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet
Apr 06Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 46% Undervaluation?
Mar 19Haemonetics Executing Well, But Valuation Dogged By Concerns About A Large Customer
Feb 16Haemonetics: Earnings Rate Of Change Justifies High Multiples
Feb 01We Think Haemonetics (NYSE:HAE) Can Manage Its Debt With Ease
Jan 05Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 36% Undervaluation?
Dec 15Haemonetics Q2 2023 Earnings Preview
Nov 04Haemonetics (NYSE:HAE) Seems To Use Debt Rather Sparingly
Oct 04Haemonetics: Plasma Thesis Continues To Play Out, Reiterate Buy
Sep 06Haemonetics reaches new 52-week high; shares up 41% YTD
Aug 24Haemonetics reports Q2 earnings beat; raises FY22 guidance
Aug 10A Look At The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)
Aug 10Here's Why Haemonetics (NYSE:HAE) Can Manage Its Debt Responsibly
Jul 03Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 3/31/2027 | 1,600 | 282 | 301 | N/A | 6 |
| 3/31/2026 | 1,471 | 226 | 253 | N/A | 10 |
| 3/31/2025 | 1,397 | 183 | 290 | N/A | 10 |
| 6/29/2024 | 1,334 | 115 | 69 | 135 | N/A |
| 3/30/2024 | 1,309 | 118 | 115 | 182 | N/A |
| 12/30/2023 | 1,270 | 127 | 129 | 197 | N/A |
| 9/30/2023 | 1,239 | 128 | 199 | 262 | N/A |
| 7/1/2023 | 1,219 | 137 | 176 | 250 | N/A |
| 4/1/2023 | 1,169 | 115 | 163 | 273 | N/A |
| 12/31/2022 | 1,129 | 96 | 128 | 261 | N/A |
| 10/1/2022 | 1,084 | 86 | 116 | 260 | N/A |
| 7/2/2022 | 1,026 | 68 | 88 | 216 | N/A |
| 4/2/2022 | 993 | 43 | 76 | 172 | N/A |
| 1/1/2022 | 953 | 23 | 33 | 106 | N/A |
| 10/2/2021 | 934 | 31 | 54 | 110 | N/A |
| 7/3/2021 | 903 | 64 | 52 | 95 | N/A |
| 4/3/2021 | 870 | 79 | 72 | 109 | N/A |
| 12/26/2020 | 884 | 108 | 118 | 154 | N/A |
| 9/26/2020 | 903 | 106 | 120 | 167 | N/A |
| 6/27/2020 | 946 | 96 | 119 | 167 | N/A |
| 3/28/2020 | 988 | 77 | 109 | 158 | N/A |
| 12/28/2019 | 999 | 80 | 81 | 132 | N/A |
| 9/28/2019 | 988 | 68 | 51 | 111 | N/A |
| 6/29/2019 | 977 | 49 | 39 | 139 | N/A |
| 3/30/2019 | 968 | 55 | 40 | 159 | N/A |
| 12/29/2018 | 952 | 46 | 72 | 196 | N/A |
| 9/29/2018 | 939 | 21 | 82 | 204 | N/A |
| 6/30/2018 | 922 | 23 | 116 | 205 | N/A |
| 3/31/2018 | 904 | 46 | N/A | 220 | N/A |
| 12/30/2017 | 898 | -17 | N/A | 197 | N/A |
| 9/30/2017 | 892 | 4 | N/A | 187 | N/A |
| 7/1/2017 | 887 | 4 | N/A | 167 | N/A |
| 4/1/2017 | 886 | -26 | N/A | 160 | N/A |
| 12/31/2016 | 900 | 16 | N/A | 178 | N/A |
| 10/1/2016 | 906 | -59 | N/A | 155 | N/A |
| 7/2/2016 | 905 | -66 | N/A | 143 | N/A |
| 4/2/2016 | 909 | -56 | N/A | 122 | N/A |
| 12/26/2015 | 893 | -50 | N/A | 124 | N/A |
| 9/26/2015 | 891 | 26 | N/A | 119 | N/A |
| 6/27/2015 | 899 | 20 | N/A | 123 | N/A |
| 3/28/2015 | 910 | 17 | N/A | 127 | N/A |
| 12/27/2014 | 925 | 30 | N/A | 123 | N/A |
| 9/27/2014 | 935 | 30 | N/A | 142 | N/A |
| 6/28/2014 | 943 | 39 | N/A | 140 | N/A |
| 3/29/2014 | 939 | 35 | N/A | 140 | N/A |
| 12/28/2013 | 947 | 38 | N/A | 116 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de HAE ( 26.4% par an) est supérieure au taux d'épargne ( 2.5% ).
Bénéfices vs marché: Les bénéfices de HAE ( 26.4% par an) devraient croître plus rapidement que le marché US ( 15.2% par an).
Croissance élevée des bénéfices: Les bénéfices de HAE devraient augmenter de manière significative au cours des 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de HAE ( 7% par an) devrait croître plus lentement que le marché de US ( 8.8% par an).
Croissance élevée des revenus: Le chiffre d'affaires de HAE ( 7% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de HAE devrait être élevé dans 3 ans ( 25.9 %)